{"id":376,"date":"2019-10-03T14:45:37","date_gmt":"2019-10-03T14:45:37","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?page_id=376"},"modified":"2020-07-08T10:31:51","modified_gmt":"2020-07-08T10:31:51","slug":"spinout-spotlight","status":"publish","type":"page","link":"https:\/\/mirm-pitt.net\/technologies\/spinout-spotlight\/","title":{"rendered":"Spinout Spotlight"},"content":{"rendered":"
\n

Vonbaerwolff<\/a><\/h2>

\"\"<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>

We offer a viable solution to the scarcity of fully functional primary human hepatocytes.<\/h4>\n

Von Baer Wolff is focused on the fabrication of human hepatocytes with one primary goal: To become the premier supplier of iPS-derived human hepatocytes to science and industry.<\/p>\n

Our technology is complex but its benefits are easy to measure. Significant cost savings, improved drug safety and effectiveness, and hope for those affected with liver disease. An abundant supply of human hepatocytes empowers researchers to explore new ideas that can positively impact patient outcomes.<\/p>\n

We follow three steps to offer this viable solution:<\/p>\n

Step 1: Make<\/strong> primary human hepatocytes from stem cells.<\/p>\n

Step 2: Modify<\/strong> them using CRISPR\/Cas9 gene-editing tools.<\/p>\n

Step 3: Mature<\/strong> and multiply them in in vivo<\/em> incubators.<\/p>\n

For the most recent news about vonbaewolff, please visit www.vonbaerwolff.com<\/a><\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div>\n<\/div><\/div>
<\/div><\/article>\n
\n

Neoolife<\/a><\/h2>

\"\"<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>

Neoolife is a Bio-MedTech start-up company based on tissue-engineering strategies and the University of Pittsburgh – Fondazione RiMED shared IPs developed within the McGowan Institute for Regenerative Medicine.<\/p>\n

Neoolife operates as a Delaware C-Corporation and includes an international and multidisciplinary team with sizeable cumulative experience in bio-med technology and device therapy for cardiovascular disease.<\/p>\n

Neoolife is focusing on polymeric heart valves and valve tissue.<\/p>\n

Neoolife’s revolutionary and unique manufacturing process allows for creating a bioengineered polymeric scaffold (no cell seeding, no animal-derived tissues). Once implanted, this scaffold is progressively replaced by newly generated and growing human heart valve tissue (endogenous in situ tissue regeneration).<\/p>\n

Neoolife’s biodegradable polymeric scaffold is made using a novel and unique electrodeposition process called double component deposition (DCD). This technology allows us to:<\/p>\n